Stockscreener 앱 받기
7.56
10.04%
0.69
시간 외 거래:
7.56
전일 마감가:
$6.87
열려 있는:
$6.8
하루 거래량:
1.26M
Relative Volume:
6.35
시가총액:
$430.53M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-6.30
EPS:
-1.2
순현금흐름:
$-58.82M
1주 성능:
+12.84%
1개월 성능:
+16.49%
6개월 성능:
+127.03%
1년 성능:
+30.57%
1일 변동 폭
$6.80
$7.93
1주일 범위
$6.16
$7.93
52주 변동 폭
$2.60
$7.93
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
7.56 | 391.34M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
Why retail investors favor Design Therapeutics Inc. stockWeekly Stock Recap & Accurate Entry/Exit Alerts - newser.com
Published on: 2025-11-08 10:43:24 - newser.com
How to interpret RSI for Design Therapeutics Inc. stockWeekly Risk Report & Advanced Swing Trade Entry Plans - newser.com
Can Design Therapeutics Inc. stock sustain institutional interestJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
Technical signs of recovery in Design Therapeutics Inc.Risk Management & Daily Profit Focused Screening - newser.com
Analyzing Design Therapeutics Inc. with risk reward ratio charts2025 Technical Overview & Free Risk Controlled Daily Trade Plans - newser.com
What indicators show strength in Design Therapeutics Inc.Market Sentiment Review & Long-Term Growth Plans - newser.com
Design Therapeutics Posts Narrower Loss And Expands Research Pipeline - Finimize
DSGN: RBC Capital Raises Price Target for Design Therapeutics | - GuruFocus
RBC Raises Price Target on Design Therapeutics to $6 From $5, Keeps Sector Perform, Speculative Risk - MarketScreener
Is Design Therapeutics Inc. stock poised for growthEarnings Risk Report & Verified Trade Idea Suggestions - newser.com
How high can Design Therapeutics Inc. stock goMarket Rally & Expert-Curated Trade Recommendations - newser.com
Why Design Therapeutics Inc. stock could outperform in 2025Entry Point & Low Risk High Reward Trade Ideas - fcp.pa.gov.br
How to integrate Design Therapeutics Inc. into portfolio analysis toolsJuly 2025 Action & Smart Allocation Stock Tips - newser.com
Design Therapeutics Reports Q3 2025 Financial Results - TipRanks
Design Therapeutics unveils DT-818 for myotonic dystrophy treatment By Investing.com - Investing.com Nigeria
Should you wait for a breakout in Design Therapeutics Inc.Trade Performance Summary & Smart Swing Trading Techniques - newser.com
Will Design Therapeutics Inc. stock outperform tech sector in 2025Rate Hike & Momentum Based Trading Ideas - fcp.pa.gov.br
Forecasting Design Therapeutics Inc. price range with options data2025 Short Interest & Capital Efficiency Focused Ideas - newser.com
Developing predictive dashboards with Design Therapeutics Inc. dataMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com
Design Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Design Therapeutics' reports lower-than-expected Q3 loss - MarketScreener
Design Therapeutics unveils DT-818 for myotonic dystrophy treatment - Investing.com
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results - The Manila Times
Design (NASDAQ: DSGN) gains ex-US regulatory clearance; DT-818 dosing DM1 H1 2026 - Stock Titan
Is Design Therapeutics Inc. forming a bottoming baseShort Setup & Smart Money Movement Alerts - newser.com
What recovery options are there for Design Therapeutics Inc.2025 Macro Impact & Consistent Income Trade Ideas - newser.com
Regression analysis insights on Design Therapeutics Inc. performance2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
Design Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 - Yahoo Finance
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
How to recover losses in Design Therapeutics Inc. stockWeekly Trade Report & Weekly Sector Rotation Insights - newser.com
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Update - MarketBeat
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.44%
0.70%
자본화:
|
볼륨(24시간):